)
Visual
test
Revolution Medicines
Revolution Medicines (RVMD) investor relations material
Revolution Medicines 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Strategic vision and mission
Aims to revolutionize treatment for RAS-addicted cancers globally through innovative targeted medicines and a robust clinical and preclinical pipeline.
Pipeline includes four clinical-stage RAS(ON) inhibitors and a fifth preclinical candidate, targeting pancreatic, non-small cell lung, and colorectal cancers.
Over 2,500 patients treated with RAS(ON) inhibitors; eight ongoing or announced registrational phase 3 trials, with additional extensive phase 1/2 trials.
Integrated workflow leverages research, clinical, and commercial insights to drive innovation and expand global reach.
Organization scaled rapidly in 2025, adding 400 employees to support global delivery of therapies.
Clinical development highlights
Pancreatic cancer is the most advanced area, with multiple registrational trials underway or planned for 2026, including monotherapy and combination regimens.
Daraxonrasib, draxanrasib, and zoldanrasib show promising efficacy, durability, and safety in pancreatic cancer, with high objective response and disease control rates in combination with FOLFIRINOX.
RMC-6236 has received a National Priority Review Voucher from the FDA.
Upcoming data releases and trial initiations for RMC-9805 and RMC-6236 in first-line metastatic pancreatic cancer.
Enrollment completed or initiated for several pancreatic cancer studies.
Non-small cell lung and colorectal cancer programs
RMC-6236 and mutant-selective inhibitors show encouraging safety and anti-tumor activity in non-small cell lung cancer; registrational trials ongoing or in advanced planning.
RASolute 301 and other registrational trials are ongoing or planned, with FDA Breakthrough Therapy Designation for RMC-9805.
Combination strategies and novel approaches are being explored in colorectal cancer, including collaborations and RAS(ON) inhibitor doublets.
First-in-human study of RMC-5127, a G12V-selective inhibitor, has been initiated.
New RAS(ON) class: target resistance mechanisms
Rationale for pioneering RAS(ON) inhibitor doublets
Daraxonrasib launch readiness: key commercial steps
How does RMO-55 address RAS-driven resistance?
Zoldonrasib's edge vs. other G12D inhibitors?
RASolute 302: What determines approval path?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebPECO
2026 FFO per share growth guided at 5.5% with record occupancy and robust acquisitions. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebNVDA
AI-driven digital twins and real-time simulation will transform engineering and manufacturing. - 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position. - 6 FebCPT
2025 results beat guidance; Sun Belt focus, asset sales, and share buybacks drive 2026 strategy. - 6 FebCRIH1 2025 saw a return to profit, record revenues, and strong cash from major space projects.
Next Revolution Medicines earnings date
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb, 2026
Revolution Medicines
Next Revolution Medicines earnings date
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Revolution Medicines Inc. is a biopharmaceutical company focused on discovering and developing targeted therapies for cancer. The company specializes in small-molecule inhibitors that address oncogenic mutations in the RAS signaling pathway, a key driver of many cancers. Revolution Medicines utilizes advanced drug discovery technologies to develop treatments for patients with genetically defined cancers. Revolution Medicines Inc. is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage